Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres

Abstract

Background:

While John Cunningham virus (JCV) is known to cause neuronal damage in progressive multifocal leukoencephalopathy (PML) among natalizumab-treated MS patients, its association with axonal loss in non-PML conditions remains unclear.

Methods:

In a cohort of 128 natalizumab-treated MS patients, serum neurofilament (sNfL) levels and JCV antibody titres were measured.

Results:

Among 128 patients (mean age = 38.4 years, 71.9% female), 51 (40%) were JCV positive. NfL levels increased by 15.3% for JCV index <0.7 (95% confidence interval [CI] = 0.963–1.381), by 18.6% for index 0.7–1.5 (95% CI = 1.009–1.394) and by 21.1% for index >1.5 (95% CI = 1.040–1.409) compared to JCV negative patients.

Conclusion:

These findings indicate a potential link between JCV burden and neuroaxonal degeneration in natalizumab-treated MS patients.

Keywords

Multiple sclerosis JCV natalizumab neurofilaments neuroaxonal loss

Get full access to this article

View all access options for this article.

References

Polman

O’Connor

Havrdova

, et al. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Rice

Hartung

Calabresi

PA.

Anti-alpha4 integrin therapy for multiple sclerosis: Mechanisms and rationale. Neurology 2005; 64(8): 1336–1342.

Plavina

Subramanyam

Bloomgren

, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76(6): 802–812.

Raffel

Gafson

Malik

, et al. Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler 2015; 21(14): 1833–1838.

Bloomgren

Richman

Hotermans

, et al. Risk of natalizumab associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.

Dalla Costa

Martinelli

Moiola

, et al. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol 2019; 85(4): 606–610.

Lee

Plavina

Castro

, et al. A second-generation ELISA (STRATIFY JCV (TM) DxSelect (TM)) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013; 57: 141–146.

White

3rd Ishaq

Stoner

, et al. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol 1992; 66(10): 5726–5734.

Loonstra

Verberk

IMW

Wijburg

, et al. Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. Ann Neurol 2019; 86(2): 322–324.

10.

Manouchehrinia

Stridh

Khademi

, et al. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology 2020; 94(23): e2457–e2467.

11.

Grut

Biström

Salzer

, et al. Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis. Brain 2024; 147: 177–185.

12.

Kapoor

Campbell

, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol 2018; 17(5): 405–415.